Apyx Medical Corporation Common Stock
APYXApyx Medical Corporation (APYX) develops and markets medical devices, primarily focusing on advanced tissue and nerve ablation techniques. The company's flagship product, Renuvion/JPlasma, uses cold plasma technology for cosmetic skin tightening, body contouring, and minimally invasive surgical procedures, promoting tissue coagulation and rejuvenation. Apyx aims to enhance aesthetic and surgical outcomes through innovative energy-based platforms.
Company News
Apyx Medical Corporation has priced a public offering of 2,762,431 shares of common stock at $3.62 per share, expecting to raise approximately $10 million for working capital and general corporate purposes.
Apyx Medical Corporation received FDA clearance for its AYON Body Contouring System, which combines multiple technologies for body contouring procedures. The company plans to launch the system with key surgeons in the second half of 2025.
Apyx Medical Corporation has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, which is designed to provide comprehensive body contouring solutions through an all-in-one platform.
Butterfly Network's stock surged 26.9% after the company announced the commercial launch of its third-generation handheld point-of-care ultrasound system, Butterfly iQ3, in Europe. The device's strong uptake in the U.S. market and its advanced features are driving investor optimism.
Apyx (APYX) delivered earnings and revenue surprises of -22.22% and 6.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
